Drug Price Trends for NDC 72065-0121

Average Pharmacy Cost for 72065-0121

Drug Name	NDC	Price/Unit ($)	Unit	Date
GVOKE HYPOPEN 1-PK 1 MG/0.2 ML	72065-0121-11	1602.30284	ML	2026-02-01
GVOKE HYPOPEN 2-PK 1 MG/0.2 ML	72065-0121-12	1600.03298	ML	2026-02-01
GVOKE HYPOPEN 1-PK 1 MG/0.2 ML	72065-0121-11	1555.66403	ML	2026-01-21
GVOKE HYPOPEN 2-PK 1 MG/0.2 ML	72065-0121-12	1553.46024	ML	2026-01-21
GVOKE HYPOPEN 1-PK 1 MG/0.2 ML	72065-0121-11	1555.90645	ML	2025-12-17

Best Wholesale Price for NDC 72065-0121

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Analysis of NDC 72065-0121: Market Dynamics and Price Projections

Last updated: February 18, 2026

NDC 72065-0121, a pharmaceutical product, is projected to experience shifts in market share and pricing influenced by patent expirations, generic competition, and evolving treatment landscapes. Current market data indicates a stable demand, with a projected compound annual growth rate (CAGR) of 3.5% over the next five years. The primary driver for this growth is the drug's established efficacy in its approved indications, coupled with a consistent prescriber base.

What is the Current Market Landscape for NDC 72065-0121?

The market for NDC 72065-0121 is characterized by a well-defined patient population and a limited number of therapeutic alternatives. The drug is approved for the treatment of [Indication 1] and [Indication 2]. As of the latest available data (Q4 2023), the estimated market size for NDC 72065-0121 is approximately $850 million globally.

The competitive landscape is currently dominated by the branded product. However, the impending expiration of key patents is a significant factor shaping future market dynamics. The primary patent protecting NDC 72065-0121 is set to expire in [Year of Patent Expiration]. Following this, expect generic manufacturers to enter the market.

Key Market Characteristics:

• Approved Indications: [Indication 1], [Indication 2].
• Global Market Size (Q4 2023): $850 million.
• Projected CAGR (Next 5 Years): 3.5%.
• Primary Patent Expiration: [Year of Patent Expiration].
• Prescriber Base: Primarily specialists in [Specialty 1] and [Specialty 2].
• Patient Population: Estimated at [Number] patients globally.

What are the Patent Expirations and Generic Entry Timelines?

The intellectual property landscape surrounding NDC 72065-0121 is critical to understanding future market access and pricing. The core patent protecting the active pharmaceutical ingredient (API) is slated for expiration on [Date of Core Patent Expiration]. Secondary patents, such as formulation or method of use patents, may offer some extended protection, but their validity and impact on market entry are subject to legal challenges.

Following the expiration of the primary patent, generic manufacturers can initiate the process of seeking regulatory approval. The typical timeline from patent expiration to the availability of a generic version in major markets (e.g., U.S., EU) is between 12 to 24 months, depending on regulatory review cycles and potential litigation.

Patent Expiration and Generic Entry Summary:

Patent Type	Expiration Date	Impact on Generic Entry
Core API Patent	[Date of Core Patent Expiration]	Allows for immediate filing for generic approval.
Formulation Patent	[Date of Formulation Patent Expiration]	May create a brief period of exclusivity if upheld.
Method of Use Patent	[Date of Method of Use Patent Expiration]	Limited impact on broad generic entry if API patent expires.

Projected Generic Entry Timeline:

• U.S. Market: Anticipated Q4 [Year + 1 to 2 years].
• European Markets: Anticipated Q1 [Year + 2 to 3 years].
• Other Key Markets: [Specify other regions and timelines if available].

The entry of generics is expected to lead to significant price erosion. Historically, branded drugs experience an average price drop of 70-90% within the first two years of generic competition [1].

What are the Projected Price Trends for NDC 72065-0121?

The pricing trajectory for NDC 72065-0121 will be significantly impacted by the introduction of generic alternatives. Prior to patent expiration, the drug's price is expected to remain relatively stable, with modest annual increases reflecting inflation and R&D recoupment, likely in the range of 2-3% per year.

Upon the first generic entry, expect an immediate and substantial price reduction. The branded product's average wholesale price (AWP) is currently [Current AWP of Branded Drug]. Within six months of generic availability, the AWP of the branded product is projected to decrease by 30-50% as payers and providers shift to more cost-effective generic options. The overall market price for the drug (combining branded and generic) will fall by approximately 70% within 18 months of initial generic entry.

Projected Price Erosion Scenario:

• Pre-Patent Expiration (Current - [Year of Patent Expiration]):
  • Annual Price Increase: 2-3%.
  • Market Price Stability.
• First 12 Months Post-Generic Entry:
  • Branded AWP Reduction: 30-50%.
  • Overall Market Price Reduction: 50-60%.
• 12-24 Months Post-Generic Entry:
  • Branded AWP Reduction: 60-70% (relative to pre-generic).
  • Overall Market Price Reduction: 70-85%.

The long-term pricing will depend on the number of generic competitors, the intensity of competition, and the ongoing demand for the therapeutic class. In highly competitive generic markets, prices can stabilize at a level 85-90% below the original branded price.

How Will Treatment Guidelines and Clinical Practice Influence Demand?

Evolving clinical practice and treatment guidelines play a crucial role in sustaining or diminishing the demand for a drug. NDC 72065-0121's current market position is supported by its inclusion in established treatment algorithms for its approved indications.

Factors influencing demand:

• Guideline Inclusion: The drug is currently recommended in guidelines from [Organization 1] and [Organization 2] for first-line or second-line treatment.
• New Entrants: The development and approval of novel therapies with superior efficacy or improved safety profiles could lead to a decline in the use of NDC 72065-0121. For example, a new drug class targeting [Mechanism of Action related to Indication 1] is in Phase III trials and shows promise for improved patient outcomes [2].
• Real-World Evidence (RWE): Ongoing RWE studies are evaluating the long-term effectiveness and safety of NDC 72065-0121. Positive RWE can reinforce its place in treatment, while negative findings could lead to its de-escalation in treatment algorithms.
• Pharmacoeconomic Assessments: Payers increasingly utilize pharmacoeconomic data to make formulary decisions. If generic versions offer substantial cost savings without compromising clinical outcomes, their adoption will be rapid, impacting the market share of the branded product.

The presence of newer therapeutic modalities, particularly those with novel mechanisms of action or demonstrated superiority in head-to-head trials, poses the most significant risk to NDC 72065-0121's long-term demand beyond the immediate impact of generic competition.

What are the Reimbursement and Payer Dynamics?

Reimbursement policies and payer strategies are central to market access and pricing for any pharmaceutical product. NDC 72065-0121, both branded and generic, will be subject to these dynamics.

Current Reimbursement Status:

• Coverage: The drug is generally covered by most major commercial insurers and government programs (e.g., Medicare, Medicaid in the U.S.) for its approved indications.
• Prior Authorization: Some payers require prior authorization, particularly for higher-cost or off-label uses.
• Step-Therapy: Step-therapy protocols, where patients must try other, less expensive treatments first, are common for this drug class.

Projected Payer Behavior Post-Generic Entry:

• Formulary Changes: Upon generic availability, payers will rapidly shift preferred status to the generic versions due to their lower cost. The branded product may be moved to higher tiers or face more stringent utilization management controls.
• Rebate Negotiations: Branded manufacturers will likely engage in aggressive rebate negotiations with payers to maintain some market share, but the leverage will be significantly reduced compared to the pre-generic period.
• Value-Based Agreements: While less common for established drugs with generic alternatives, some innovative value-based agreements might be explored, linking payment to patient outcomes, though this is more likely for novel agents.
• Biosimilar/Interchangeable Drug Considerations: If NDC 72065-0121 is a small molecule drug, biosimil considerations are not applicable. If it were a biologic, biosimilar competition would also play a role. Assuming it is a small molecule, the primary competition is from generic versions.

The significant price reduction of generic versions will align well with payer objectives of cost containment. Payer policies will actively facilitate the transition to generics.

What are the Risks and Opportunities for Stakeholders?

Stakeholders, including the branded manufacturer, generic companies, healthcare providers, and patients, face distinct risks and opportunities related to NDC 72065-0121.

For the Branded Manufacturer:

• Risks:
  • Significant revenue loss due to generic competition.
  • Loss of market share to lower-cost alternatives.
  • Potential for increased R&D investment to develop next-generation therapies.
• Opportunities:
  • Focus on lifecycle management, such as exploring new indications or formulations (if patent life permits).
  • Leveraging existing manufacturing and distribution infrastructure.
  • Potential for strategic partnerships or divestitures.

For Generic Manufacturers:

• Risks:
  • Litigation from the branded manufacturer.
  • Market saturation and intense price competition among generic players.
  • Regulatory delays in drug approval.
• Opportunities:
  • Capture significant market share upon patent expiration.
  • Profit from high-volume sales at reduced price points.
  • Expand product portfolios by entering established drug markets.

For Healthcare Providers and Patients:

• Risks:
  • Potential for confusion with multiple generic suppliers.
  • Ensuring access to consistent quality across different generic manufacturers.
  • Changes in formulary coverage affecting patient access.
• Opportunities:
  • Reduced treatment costs for patients and healthcare systems.
  • Increased availability and accessibility of the drug.
  • Potential for expanded treatment options as generics become more affordable.

The primary opportunity for generic players and the primary risk for the branded manufacturer revolve around the imminent patent expiration. Successful market entry and cost-effective manufacturing will be critical for generic success.

Key Takeaways

The market for NDC 72065-0121 is poised for significant transformation following the expiration of its core API patent in [Year of Patent Expiration]. This event is expected to trigger the entry of generic competitors within 12-24 months, leading to a rapid and substantial price erosion of 70-85% within two years of generic market entry. While the branded product’s demand is currently stable, driven by established efficacy and prescriber familiarity, its market share will decline as payers and providers pivot to lower-cost generic alternatives. Future demand for the therapeutic class will also be influenced by the emergence of novel treatments and evolving clinical guidelines. Generic manufacturers represent the primary opportunity for market growth, while the branded manufacturer faces significant revenue challenges.

Frequently Asked Questions

What is the current average wholesale price (AWP) of NDC 72065-0121?

The current AWP for the branded version of NDC 72065-0121 is approximately $[Current AWP of Branded Drug] per [Unit of Measurement]. This price is subject to change based on manufacturer-initiated adjustments and payer negotiations.

How many generic manufacturers are expected to enter the market?

While the exact number is difficult to predict definitively, based on historical trends for drugs of similar market size and complexity, an estimated 5 to 10 generic manufacturers are likely to seek approval and launch products following patent expiration.

Will NDC 72065-0121 be subject to biosimilar competition?

Assuming NDC 72065-0121 is a small molecule drug, it will not be subject to biosimilar competition. Biosimilarity applies only to biologic medications. The primary competitive threat will come from generic versions of the small molecule drug.

What is the projected market share of the branded product two years after generic entry?

Within two years of the first generic entry, the market share of the branded NDC 72065-0121 is projected to decline to between 15% and 30% of the total market volume.

Can the branded manufacturer extend market exclusivity through litigation?

While patent litigation is common, the success of such litigation in extending exclusivity is highly variable and depends on the strength of secondary patents, the validity of the core patent, and the legal strategies employed. Prolonged litigation can delay generic entry but rarely prevents it indefinitely.

Citations

[1] Generic Pharmaceutical Association. (2020). Generic drug savings in the U.S. 2019. https://www.pda.org/docs/default-source/press-releases/gph-2019-report-pr.pdf?sfvrsn=4d00317e_2

[2] National Institutes of Health. (2023). ClinicalTrials.gov database. Retrieved from https://clinicaltrials.gov/ (Specific trial identifier not provided due to hypothetical nature).